Unknown

Dataset Information

0

Effects of ?-blockers on all-cause mortality in patients with type 2 diabetes and coronary heart disease.


ABSTRACT:

Aims

To assess whether the use of beta-blockers influences mortality and the incidence of major cardiovascular events in patients with diabetes and coronary heart disease (CHD).

Materials and methods

Using data from the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial, we performed Cox proportional hazards analysis to assess the effects of ?-blockers on all-cause mortality in 2244 patients with type 2 diabetes who had stable CHD with and without a history of myocardial infarction (MI)/heart failure with reduced left ventricular ejection fraction (HFrEF).

Results

All-cause mortality in patients with MI/HFrEF was significantly lower in those receiving ?-blockers than in those not receiving ?-blockers (adjusted hazard ratio [HR] 0.60, 95% confidence interval [CI] 0.37-0.98; P ?=?.04), whereas that in patients without MI/HFrEF did not significantly differ (adjusted HR 0.91, 95% CI 0.76-1.32; P ?=?.64). Among patients with MI/HFrEF, all-cause mortality in those who received intensive medical therapy alone for CHD was significantly lower in those on ?-blockers than in those not on ?-blockers (adjusted HR 0.45, 95% CI 0.23-0.88; P ?=?.02); however, mortality in patients who received early revascularization for CHD was not significantly lower in those on ?-blockers (adjusted HR 0.81, 95% CI 0.40-1.65; P ?=?.57). The risk of major cardiovascular events in patients without MI/HFrEF was not significantly different between those on and those not on ?-blocker treatment.

Conclusions

In patients with diabetes and CHD, the use of ?-blockers was effective in reducing all-cause mortality in those with MI/HFrEF but not in those without MI/HFrEF.

SUBMITTER: Tsujimoto T 

PROVIDER: S-EPMC5484336 | biostudies-literature | 2017 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Effects of β-blockers on all-cause mortality in patients with type 2 diabetes and coronary heart disease.

Tsujimoto Tetsuro T   Sugiyama Takehiro T   Kajio Hiroshi H  

Diabetes, obesity & metabolism 20170217 6


<h4>Aims</h4>To assess whether the use of beta-blockers influences mortality and the incidence of major cardiovascular events in patients with diabetes and coronary heart disease (CHD).<h4>Materials and methods</h4>Using data from the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial, we performed Cox proportional hazards analysis to assess the effects of β-blockers on all-cause mortality in 2244 patients with type 2 diabetes who had stable CHD with and without a history of myo  ...[more]

Similar Datasets

| S-EPMC9911879 | biostudies-literature
| S-EPMC4485950 | biostudies-literature
| S-EPMC3114476 | biostudies-literature
| S-EPMC3670852 | biostudies-literature
| S-EPMC9333402 | biostudies-literature
| S-EPMC3058601 | biostudies-literature
| S-EPMC10375079 | biostudies-literature
| S-EPMC4120268 | biostudies-literature
| S-EPMC10401778 | biostudies-literature
| S-EPMC5946410 | biostudies-literature